In Vitro Susceptibility to Pexiganan of Bacteria Isolated from Infected Diabetic Foot Ulcers
|
|
- Alan Webb
- 6 years ago
- Views:
Transcription
1 In Vitro Susceptibility to Pexiganan of Bacteria Isolated from Infected Diabetic Foot Ulcers Yigong Ge, Dorothy MacDonald, Marietta M. Henry, Howard I. Hait, Kimberly A. Nelson, Benjamin A. Lipsky, Michael A. Zasloff, and Kenneth J. Holroyd During two clinical trials involving the treatment of 835 outpatients with infected diabetic foot ulcers, 2515 bacterial isolates, including 2337 aerobes and 178 anaerobes, were grown from cultures of the ulcers. The in vitro susceptibility of these isolates was determined to pexiganan, a peptide anti-infective evaluated in these clinical trials, and to other classes of antibiotics. Pexiganan demonstrated broad spectrum antimicrobial activity against Gram-positive and Gram-negative aerobes and anaerobes. The MIC 90 values for the most common species among 1735 Gram-positive aerobes isolated, such as Staphylococcus aureus, coagulase-negative staphylococci, Group A streptococci, and Group B streptococci, were 16 g/ml or less. Of 602 Gram-negative aerobes tested, the MIC 90 values for pexiganan were 16 g/ml or less for Acinetobacter, Pseudomonas, Stenotrophomonas, Citrobacter, Enterobacter, Escherichia, Klebsiella, and Flavobacterium species. Pexiganan had a MIC 90 of4to16 g/ml against the anaerobic isolates of Bacteroides, Peptostreptococcus, Clostridium, and Prevotella species. Importantly, pexiganan did not exhibit cross-resistance with other commonly used antibiotics, including -lactams, quinolones, macrolides, and lincosamides. The broad spectrum in vitro antimicrobial activity of pexiganan against clinical isolates from infected diabetic foot ulcers supports its potential as a local therapy for infected diabetic foot ulcers Elsevier Science Inc. INTRODUCTION From the Magainin Pharmaceuticals Inc. (YG, DM, HIH, KAN, MAZ, KJH), Plymouth Meeting, PA, USA, Covance Central Laboratory Services Inc. (MMH), Indianapolis, IN, USA, Medical Service, VA Puget Sound Health Care System, and Department of Medicine, University of Washington School of Medicine (BAL), Seattle, WA, USA. Address reprint requests to Department of Microbiology, Magainin Pharmaceuticals Inc., Plymouth Meeting, PA Received 5 January 1999; revised and accepted 21 April Lower extremity infections are among the most common and serious complications of diabetes mellitus. They are the most frequent cause of hospitalization for diabetics, and account for approximately 6% of all hospitalizations in the United States (Levin, 1997; Reiber et al., 1998). The management of infected diabetic foot ulcers imposes a substantial financial burden on society. According to recent estimates, medical costs run as high as $4600 to $9900 per ulcer episode (Holzer et al., 1998; Obrien et al., 1998). In addition to management of the blood glucose, treatment of diabetic foot ulcer infections requires vigorous wound care and antimicrobial chemotherapy. The antibiotic regimens most often recommended for the treatment of these potentially serious infections consist of orally or parenterally administered broad spectrum agents, such as amoxicillin/clavulanate, ampicillin/sulbactam, ofloxacin, ciprofloxacin, imipenem, piperacillin/tazobactam, and second or third generation cephalosporins (Grayson et al., 1994; Lipsky et al., 1990; Lipsky, 1999; West, 1995). At the present time, no local antibiotic therapy has been demonstrated to be effective in the treatment of diabetic foot ulcer infections. Magainins are a novel class of peptide antiinfectives originally isolated from the skin of the DIAGN MICROBIOL INFECT DIS 1999;35: Elsevier Science Inc. All rights reserved /99/$ see front matter 655 Avenue of the Americas, New York, NY PII S (99)
2 46 Y. Ge et al. African clawed frog, Xenopus laevis (Zasloff, 1988). Like other cationic peptide antimicrobials, magainins act by binding to anionic phospholipids on the outer leaflet of bacterial membranes, leading to perturbation of membrane permeability, and subsequently bacterial cell lysis and death (Boman, 1995; Hancock, 1997; Jacob and Zasloff, 1994; Nicolas and Mor, 1995). Based on this mechanism of action, the predicted likelihood of bacterial resistance against this class of antibiotic is low (Boman, 1995; Hancock, 1997; Jacob and Zasloff, 1994; Nicolas and Mor, 1995). Through extensive structure activity studies, pexiganan, an analog of Magainin 2 (a natural antimicrobial peptide compound isolated from the frog skin) was created with a potency and safety profile that supported its development as a therapeutic agent for the treatment of diabetic foot infections (Lipsky et al., 1997). Pexiganan (MSI-78) is a broad spectrum bactericidal agent active in vitro against both anaerobic and aerobic microorganisms (Fuchs et al., 1998; Ge et al., 1999). Recently, pexiganan has been evaluated in the treatment of outpatient diabetic foot ulcer infections in two placebo controlled double blind trials, comparing pexiganan cream 1% to orally administered ofloxacin (Lipsky et al., 1997). In this report, we present the in vitro pexiganan susceptibility of 2515 isolates cultured from infected diabetic foot ulcers. MATERIALS AND METHODS Patients A total of 835 adult diabetic outpatients clinically judged to have an infected foot ulcer were enrolled in two phase 3 studies comparing pexiganan cream 1% to oral ofloxacin. Patients were drawn from 81 medical centers widely distributed geographically across the United States. Institutional Review Board approval of the protocol was obtained at each medical center, and informal consent was obtained from each patient. Excluded were patients whose foot ulcer was complicated by osteomyelitis, advancing cellulitis, tendon or bone exposure, deep abscess requiring surgical drainage, or infections judged to require hospitalization. Specimen collection and Microorganism Isolation A standard and well validated (Lipsky et al., 1990) specimen collection protocol was established in all clinical centers. In brief, a culture sample was collected by tissue curettage during the debridement procedure; the tissue was obtained from the base of the ulcer, and placed in transport medium (Port-A- Cul Tube, Becton Dickinson Co., Cockeysville, MD, USA). Specimens were shipped by overnight mail to the testing center (Corning SciCor, Indianapolis, IN, USA) where the plating of cultures, identification of isolates, and susceptibility tests (see below) were performed. Cultures were obtained at the baseline visit, on Days 3, 10, 14, 21, 28, and at a 2 week post therapy follow-up visit. Where multiple isolates of the same species were obtained from a patient, only the first isolate collected is presented in this report. For example, if a Staphylococcus aureus was isolated at the baseline visit, on Day 3 and Day 28, only the result at the baseline visit is included in this report. Antimicrobial Agents The peptide pexiganan (Gly-Ile-Gly-Lys-Phe-Leu- Lys-Lys-Ala-Lys-Lys-Phe-Gly-Lys-Ala-Phe-Val-Lys- Ile-Leu-Lys-Lys-NH 2 ) was synthesized at Bachem Bioscience (Torrance, CA, USA). Pexiganan (powder) was dissolved in water prior to use. Other antimicrobial agents used were obtained from Sigma Chemicals (St. Louis, MO, USA) and their respective United States manufacturers. In Vitro Susceptibility Testing All susceptibility testing was performed at Corning SciCor (Indianapolis, IN, USA). The minimum inhibitory concentration (MIC) of pexiganan and other antimicrobials to both aerobic and anaerobic microorganisms was determined in broth and/or disk diffusion assays according to the NCCLS recommended procedures (NCCLS, 1987; NCCLS, 1993; NCCLS, 1997). Unsupplemented Mueller-Hinton broth (to avoid any interference of cations with in vitro pexiganan activity) and the anaerobic MIC broth (Wilkins-Chalgren) were used in testing most aerobic bacteria and anaerobic bacteria, respectively. Resistance breakpoints were determined by NCCLS criteria when available. When NCCLS criteria were not available, as was the case for anaerobic isolates tested with oxacillin, ofloxacin, cephalexin, and amikacin, the following breakpoints were used: ofloxacin ( 8.0 g/ml), oxacillin ( 8.0 g/ml), cephalexin ( 32 g/ml), and amikacin ( 32 g/ml). Eight quality control (QC) organisms, including Enterococcus faecalis ATCC 29212, S. aureus ATCC 29213, Escherichia coli ATCC 25922, E. coli ATCC 35218, Pseudomonas aeruginosa ATCC 27853, Bacteroides fragilis ATCC 25285, Bacteroides thetaiotaomicron ATCC 29741, and Eubacterium lentum ATCC 43055, were tested along with clinical isolates to monitor testing quality.
3 In Vitro Susceptibility Pexiganan 47 RESULTS In Vitro Antibacterial Activity of Pexiganan To evaluate the activity of pexiganan against clinical isolates from diabetic foot ulcers, MICs were determined for a total of 2515 isolates. These isolates, that consisted of 2337 aerobes and 178 anaerobes, included pathogens commonly associated with complicated skin and soft tissue infections. Pexiganan demonstrated good activity against the majority of aerobic species tested (Table 1). Most aerobic bacteria, including staphylococci, some Streptococcus species, Corynebacterium spp., and Micrococcus spp., exhibited an MIC 90 of 16 g/ml or less. Importantly, the MIC 90 for most of the more prevalent Grampositive pathogens, such as S. aureus (375 isolates), Staphylococcus epidermidis (194 isolates), Staphylococcus hemolyticus (81 isolates), Streptococcus agalactiae (174 isolates), and Streptococcus pyogenes (11 isolates), was 16 g/ml or less. Limited numbers of other Gram-positive aerobic bacteria, including Aerococcus spp., Arcanobacterium spp., Bacillus spp., Brevibacterium spp., Gemella morbillorum, Oerskovia spp., and Rhodococcus equi, were also inhibited by pexiganan with an MIC of 16 g/ml or less. Pexiganan was less active against Streptococcus mitis (14 isolates), Streptococcus sanguis (38 isolates), and E. faecalis (325 isolates) with an MIC 90 of 128 to 256 g/ml. Enterococcus spp. other than E. faecalis exhibited an MIC 90 of 32 g/ml. These results suggest that pexiganan has in vitro activity against most Gram-positive aerobes. Pexiganan also exhibited good activity against Gram-negative bacteria (Table 2). Of the 602 isolates tested, pexiganan at a concentration of 16 g/ml or less inhibited the growth of 90% of isolates of Acinetobacter, Pseudomonas, Stenotrophomonas, Citrobacter, Enterobacter, Escherichia, Klebsiella, and Flavobacterium species. Several species not commonly implicated as pathogens in skin infections, including Capnocytophaga, Hemophilus, Neisseria, and Moraxella, were also isolated and inhibited by pexiganan (MICs 8 g/ ml). Pexiganan was less active against Alcaligenes faecalis with a MIC 90 of 256 g/ml, and a MIC 50 of 32 g/ml. Several closely related genera of the Enterobacteriaceae family, including Morganella, Proteus, Providencia, and Serratia, were found to be less susceptible in vitro to pexiganan, with both MIC 50 and MIC 90 greater than 256 g/ml. As shown in Table 3, pexiganan demonstrated excellent antimicrobial activity against anaerobic pathogens (177 isolates) recovered from diabetic foot ulcer infections. The MIC 90 for species of Bacteroides, Peptostreptococcus, and Prevotella, was 16 g/ml or less. All obligate anaerobes, including Clostridium, Propionibacterium, Mobiluncus, Fusobacterium, and Veillonella, were also inhibited by pexiganan at a concentration of 8 g/ml or less, although the number of isolates tested was limited. To monitor test quality and reproducibility, eight NCCLS quality control organisms were tested along with clinical isolates. A summary of all quality control testing results are shown in Table 4. Consistent and reproducible results were obtained with these quality control strains. The differences of the MICs in a specific QC strain were limited to one or two doubling dilutions (32 to 64 g/ml for E. faecalis ATCC 29212, 8 to 16 g/ml for S. aureus ATCC 29213, 4 to 8 g/ml for E. coli ATCC and E. coli ATCC 35218, 4 to 8 g/ml for Pseudomonas aeruginosa ATCC 27853, 2 to 8 g/ml for Bacteroides fragilis ATCC 25285, 2 to 8 g/ml for Bacteroides thetaiotaomicron ATCC 29741, and 4 to 16 g/ml for Eubacterium lentum ATCC 43055). Lack of Cross-Resistance between Pexiganan and other Classes of Antibiotics In addition to pexiganan, the in vitro susceptibility of the clinical isolates from diabetic foot ulcer infections was determined for other classes of antibiotics including -lactams, macrolides, quinolones, lincosamides, and aminoglycosides. The percentage and number of resistant isolates for each antibiotic tested are presented in Tables 1 to 3. To evaluate potential cross-resistance of pexiganan with other classes of antibiotics, the susceptibility data of isolates from the infected diabetic foot ulcers resistant to these other antibiotics were analyzed. These isolates included oxacillin (methicillin)-resistant staphylococci, quinolone-resistant staphylococci and Corynebacterium spp., erythromycin-resistant Corynebacterium species, clindamycin-resistant staphylococci, cephalosporin-resistant staphylococci, and imipenem-resistant S. epidermidis and S. hemolyticus. Table 5 lists the MIC distributions, MIC 50 and MIC 90 against pexiganan for these isolates in relationship to their susceptibility to other classes of antibiotics. There was no correlation between resistance to the other agents and higher MICs to pexiganan. The distribution of MICs against pexiganan was similar for organisms either resistant or susceptible to these other antibiotics. In each case, the differences in MIC 50 and MIC 90 between resistant and susceptible populations were no more than two-fold. Similarity of In Vitro Susceptibility to Pexiganan of Isolates Recovered from Infected Diabetic Foot Ulcers and Clinical Strains Isolated from Non-Diabetic Disorders The susceptibility patterns of clinical strains recovered from infections of non-diabetic foot ulcer origin (NDFU) were compared with identical species recov-
4 48 Y. Ge et al. TABLE 1 MICs of Infected Diabetic Foot Ulcer Gram-Positive Aerobic Bacteria to Pexiganan; % Resistant (by NCCLS Criteria) to Several Oral or Intravenous Antibiotics MIC ( g/ml) with Pexiganan Percentage of Resistant Isolates (number of resistant isolates) isolates MIC 50 MIC 90 Range Ofloxacin Oxacillin Amoxicillin/ Clavulanate Clindamycin Cephalexin Erythromycin Imipenem Staphylococcus S. aureus (59) 13 (50) 9 (34) 14 (51) 12 (46) 27 (102) 4 (15) S. epidermidis (112) 61 (118) 3 (5) 25 (48) 53 (72) 72 (139) 16 (31) S. haemolyticus (50) 57 (46) 41 (33) 30 (24) 57 (46) 67 (54) 27 (22) S. hominis (0) 0 (0) 0 (0) 0 (0) 5 (1) 15 (3) 0 (0) S. sciuri (6) 33 (12) 3 (1) 14 (5) 19 (7) 28 (10) 0 (0) S. simulans (10) 26 (11) 12 (5) 17 (7) 24 (10) 29 (12) 12 (5) Other coagulase negative staphylococci (13) 14 (10) 0 (0) 11 (8) 10 (7) 28 (20) 1 (1) Streptococcus S. agalactiae (2) 1 (2) 0 (0) 4 (7) 2 (4) 9 (16) 0 (0) S. canis (4) 0 (0) 0 (0) 2 (1) 0 (0) 11 (5) 0 (0) S. mitis (1) 29 (4) 0 (0) 7 (1) 29 (4) 29 (4) 0 (0) S. pyogenes (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) S. sanguis (5) 13 (5) 0 (0) 3 (1) 11 (4) 5 (2) 0 (0) Other streptococci (11) 12 (8) 0 (0) 8 (5) 9 (6) 8 (5) 2 (1) Enterococcus E. faecalis (37) 99 (321) 1 (4) 98 (317) 99 (323) 34 (112) 1 (3) E. faecium (4) 93 (14) 0 (0) 73 (11) 47 (7) 47 (7) 7 (1) Other enterococci (2) 89 (16) 0 (0) 89 (16) 22 (4) 28 (5) 0 (0) Corynebacterium C. jeikeium (9) 67 (10) 13 (2) 67 (10) 27 (4) 40 (6) 7 (1) C. minutissimum (24) 55 (17) 0 (0) 74 (23) 3 (1) 48 (15) 3 (1) C. striatum (19) 83 (38) 2 (1) 44 (20) 2 (1) 18 (8) 0 (0) C. xerosis (10) 68 (13) 0 (0) 53 (10) 0 (0) 11 (2) 0 (0) Other Corynebacterium spp (34) 61 (36) 10 (6) 56 (34) 22 (13) 27 (16) 5 (3) Micrococcus spp (5) 43 (6) 14 (2) 14 (2) 21 (3) 14 (2) 7 (1) Other gram-positive bacteria Aerococcus spp (1) 80 (8) 0 (0) 10 (1) 0 (0) 40 (4) 0 (0) Arcanobacterium spp ND 8 16 ND (2) ND (0) ND (0) ND (0) ND (0) ND (0) ND (0) Bacillus spp. 3 8 ND 2 8 ND (0) ND (2) ND (0) ND (1) ND (2) ND (0) ND (0) Brevibacterium spp. 3 2 ND ND (2) ND (0) ND (0) ND (1) ND (0) ND (0) ND (0) Gemella morbillorum 2 4 ND 4 8 ND (0) ND (1) ND (1) ND (0) ND (1) ND (0) ND (0) Oerskovia spp. 3 4 ND 2 8 ND (0) ND (3) ND (0) ND (2) ND (3) ND (1) ND (3) Rhodococcus equi 2 1 ND 1 ND (1) ND (1) ND (0) ND (1) ND (0) ND (0) ND (0) Total 1735 ND For species with less than 10 isolates, the MIC 90 and the percentage of resistance was not calculated, and for species with less than two isolates, the MIC 50 was not determined.
5 In Vitro Susceptibility Pexiganan 49 TABLE 2 MICs of Gram-Negative Aerobic Bacteria to Pexiganan; % Resistant (by NCCLS Criteria) to Several Oral or Intravenous Antibiotics MIC ( g/ml) with Pexiganan Percentage of Resistant Isolates (number of resistant isolates) Isolates MIC 50 MIC 90 Range Ofloxacin Ampicillin Amoxicillin/ Clavulanate Amikacin Ceftazidime Imipenem Acinetobacter A. anitratus (2) 23 (9) 13 (5) 5 (2) 0 (0) 0 (0) A. baumanii (1) 16 (3) 5 (1) 11 (2) 5 (1) 5 (1) Other Acinetobacter spp (0) 8 (1) 0 (0) 0 (0) 0 (0) 0 (0) Alcaligenes A. faecalis (3) 10 (2) 0 (0) 0 (0) 0 (0) 0 (0) Other Alcaligenes spp ND ND (2) ND (1) ND (0) ND (5) ND (1) ND (0) Pseudomonas P. aeruginosa (14) 99 (91) 99 (91) 0 (0) 0 (0) 2 (2) Other Pseudomonas spp. 7 4 ND 1 8 ND (3) ND (3) ND (1) ND (0) ND (3) ND (0) Stenotrophomonas S. maltophilia (7) 78 (29) 78 (29) 70 (26) 14 (5) 92 (34) Enterobacteriaceae Citrobacter C. diversus 9 4 ND 4 ND (0) ND (7) ND (0) ND (0) ND (0) ND (0) C. freundii 9 4 ND 2 8 ND (1) ND (2) ND (8) ND (0) ND (1) ND (0) Enterobacter E. cloacae (0) 67 (33) 80 (39) 0 (0) 0 (0) 0 (0) Other Enterobacter spp (0) 33 (4) 25 (3) 0 (0) 0 (0) 0 (0) Escherichia E. coli (1) 30 (16) 9 (5) 2 (1) 2 (1) 0 (0) Other Escherichia spp. 2 4 ND 4 8 ND (0) ND (0) ND (0) ND (0) ND (0) ND (0) Hafnia H. alvei 1 ND ND 4 ND (0) ND (0) ND (0) ND (0) ND (0) ND (0) Klebsiella K. oxytoca (1) 65 (20) 0 (0) 0 (0) 0 (0) 0 (0) K. pneumoniae (0) 54 (13) 0 (0) 0 (0) 4 (1) 3 (1) Morganella M. morganii (1) 100 (13) 100 (13) 0 (0) 0 (0) 0 (0) Proteus P. mirabilis (0) 7 (4) 2 (1) 0 (0) 3 (2) 2 (1) Other Proteus spp (0) 85 (11) 0 (0) 0 (0) 0 (0) 0 (0) Providencia P. rettgeri (1) 17 (2) 42 (5) 0 (0) 0 (0) 0 (0) P. stuartii ND 256 ND (0) ND (3) ND (3) ND (0) ND (0) ND (0) Serratia S. marcescens (0) 57 (20) 89 (31) 0 (0) 0 (0) 0 (0) Other Serratia spp ND ND (0) ND (2) ND (2) ND (0) 0 (0) ND (0) Yokenella regensburgi 1 ND ND 256 ND (0) ND (0) ND (1) ND (0) 0 (0) ND (0) Other gram-negative bacteria spp. Aeromonas spp ND ND (0) ND (1) ND (1) ND (0) ND (0) ND (0) Capnocytophaga spp. 1 ND ND 4 ND (1) ND (1) ND (1) ND (0) ND (0) ND (0) Chryseomonas luteola 1 ND ND 4 ND (0) ND (1) ND (0) ND (0) ND (0) ND (0) Flavobacterium spp (0) 38 (5) 38 (5) 38 (5) 31 (4) 23 (3) Haemophilus spp. 8 4 ND ND (0) ND (1) ND (0) ND (0) ND (0) ND (0) Neisseria meningitides 1 ND ND 4 ND (0) ND (0) ND (0) ND (0) ND (0) ND (0) Moraxella spp. 2 4 ND 4 ND (0) ND (0) ND (0) ND (0) ND (0) ND (0) Pasteuralla spp. 4 4 ND 1 8 ND (0) ND (0) ND (0) ND (0) ND (0) ND (0) Total 602 ND For species with less than 10 isolates, the MIC 90 and the percentage of resistance was not calculated, and for species with less than two isolates, the MIC 50 was not determined.
6 50 Y. Ge et al. TABLE 3 MICs of Anaerobic Bacteria to Pexiganan; % Resistant (by NCCLS Criteria) b to Several Oral or Intravenous Antibiotics MIC ( g/ml) with Pexiganan Percentage of Resistance (numbers of resistance isolates) Isolates Amoxicillin/ MIC 50 MIC 90 Range Ofloxacin a Oxacillin a Clavulanate Clindamycin Cephalexin a Amikacin a Gram-positive Clostridium C. clostridioforme 1 ND ND 4 ND (1) ND (0) ND (0) ND (0) ND (1) ND (1) C. paraputrificum 1 ND ND 1 ND (0) ND (0) ND (0) ND (0) ND (0) ND (0) Lactobacillus spp ND ND (1) ND (0) ND (0) ND (0) ND (0) ND (2) Peptostreptococcus P. asaccharolyticus (13) 12 (2) 0 (0) (1) 6 (1) 6 (1) P. magnus (19) 3 (1) 0 (0) 11 (4) 0 (0) 8 (3) P. prevotii (6) 9 (1) 0 (0) 20 (2) 0 (0) 9 (1) Other Peptostreptococcus spp (4) 0 (0) 0 (0) 27 (3) 9 (1) 9 (1) Propionibacterium P. acnes 1 ND ND 1 ND (0) ND (0) ND (0) ND (0) ND (0) ND (0) Mobiluncus spp. 1 ND ND 2 ND (0) ND (0) ND (0) ND (0) ND (0) ND (0) Gram-negative Bacteroides B. fragilis (13) 96 (26) 0 (0) 7 (2) 93 (25) 100 (27) Other Bacteroides spp (9) 81 (13) 0 (0) 25 (4) 75 (12) 81 (13) Fusobacterium F. necrophorum 1 ND ND 4 ND (0) ND (0) ND (0) ND (0) ND (0) ND (0) F. nucleatum 1 ND ND 4 ND (1) ND (0) ND (0) ND (0) ND (0) ND (1) F. varium 1 ND ND 4 ND (0) ND (0) ND (0) ND (1) ND (0) ND (0) Prevotella P. bivia (8) 56 (19) 6 (2) 12 (4) 24 (8) 85 (29) Other Prevotella spp (3) 64 (7) 9 (1) 18 (2) 45 (5) 91 (10) Veillonella spp. 5 2 ND 2 8 ND (3) ND (2) ND (0) ND (0) ND (0) ND (1) Total 178 a ND For species with less than 10 isolates, the MIC90 and the percentage of resistance was not calculated, and for species with less than two isolates, the MIC 50 was not determined. b Resistance breakpoints for anaerobes used the following breakpoints when no NCCLS criteria were available: ofloxacin ( 8.0 g/ml), oxacillin ( 8.0 g/ml), cephalexin ( 32 g/ml), and amikacin ( 32 g/ml); those for amoxicillin/clavulanate, and clindamycin were based on NCCLS criteria.
7 In Vitro Susceptibility Pexiganan 51 TABLE 4 MIC Distributions of Pexiganan With the QC Strains Tested MIC Distribution for the QC Strains ( g/ml) test S. aureus ATCC E. faecalis ATCC E. coli ATCC E. coli ATCC P. aeruginosa ATCC B. fragilis ATCC B. thetaiotaomicron ATCC E. lentum ATCC TABLE 5 Comparison of MIC Distributions to Pexiganan for Infected Diabetic Foot Ulcer Isolates Resistant (Based on NCCLS Criteria) and Susceptible to Other Antibiotics isolates MIC ( g/ml) MIC 50 MIC 90 Oxacillin resistant S. aureus Oxacillin susceptible S. aureus Oxacillin resistant S. epidermidis and S. haemolyticus Oxacillin susceptible S. epidermidis and S. haemolyticus Ofloxacin resistant S. aureus Ofloxacin susceptible S. aureus Ofloxacin resistant S. epidermidis and S. haemolyticus Ofloxacin susceptible S. epidermidis and S. haemolyticus Ofloxacin resistant Corynebacterium Ofloxacin susceptible Corynebacterium Ofloxacin resistant anaerobes Ofloxacin susceptible anaerobes Amoxicillin/clavulanate resistant S. haemolyticus Amoxicillin/clavulanate susceptible S. haemolyticus Erythromycin resistant Corynebacterium Erythromycin susceptible Corynebacterium Clindamycin resistant S. aureus, S. epidermidis and S. haemolyticus Clindamycin susceptible S. aureus, S. epidermidis and S. haemolyticus Imipenem resistance S. epidermidis and S. haemolyticus Imipenem susceptible S. epidermidis and S. haemolyticus Cephalexin resistant S. aureus Cephalexin susceptible S. aureus Cephalexin resistant S. epidermidis and S. haemolyticus Cephalexin susceptible S. epidermidis and S. haemolyticus
8 52 Y. Ge et al. ered from diabetic foot ulcers (DFU). The pexiganan susceptibility data for the NDFU group used in Table 6 was adopted from our previous in vitro susceptibility study (Ge et al., 1999). Table 6 shows the distributions of MIC 50 and MIC 90 of the various isolates. For Gram-positive bacteria, there was no remarkable difference in the MIC distribution between the NFDU and DFU isolates, except for the lower MIC 50 and MIC 90 for E. faecalis in the DFU. Interestingly, MIC 50 and/or MIC 90 were lower in the DFU than those of the NDFU for the majority of Gram-negative aerobic bacteria, such as Enterobacteriaceae, Acinetobacter, Pseudomonas, and Stenotrophomonas. A similar pattern was also found in two species of anaerobic microorganisms; the MIC 90 of Peptostreptococcus and Prevotella in the DFU group were two-fold lower than those of the NDFU. In brief, the MIC 50 and MIC 90 of the DFU isolates were identical or lower than those of the NDFU isolates, with the exception of the MIC 90 for Alcaligenes faecalis. These findings suggest that clinical isolates from diabetic foot lesions exhibit a similar susceptibility to pexiganan as previously observed for clinical isolates recovered from other disease states. DISCUSSION Pexiganan demonstrated broad spectrum in vitro antimicrobial activity against most of the common pathogens isolated from infected diabetic foot ulcers. Several closely related genera of the Enterobacteriaceae family, including Morganella, Proteus, Providencia, and Serratia, were found to be the less susceptible in vitro to pexiganan, with both MIC 50 and MIC 90 greater than 256 g/ml. Interestingly, all four of these species have a close genetic relationship. The precise mechanism underlying the in vitro intrinsic relative resistance of these species is not yet understood. In its current formulation, pexiganan is administered as a 1% (10,000 g/ml) concentration in a cream base. Application at this concentration could provide anti-infective efficacy even against infected diabetic foot ulcer organisms less susceptible in vitro TABLE 6 Comparison of Susceptibility to Pexiganan for Clinical Isolates from Non-Diabetic Disorders and Infected Diabetic Foot Ulcers a MIC ( g/ml) MIC ( g/ml) isolates MIC 50 MIC 90 Staphylococcus aureus DBF NDFU Coagulase-negative DBF staphylococci NDFU Streptococci b DBF NDFU Enterococcus faecalis DBF NDFU Corynebacterium spp. DBF NDFU Enterobacteriaceae c DBF NDFU Acinetobacter spp. DBF NDFU Alcaligenes spp. DBF NDFU Pseudomonas spp. DBF NDFU S. maltophilia DBF NDFU Bacteroides spp. DBF NDFU Peptostreptococcus spp. DBF NDFU Prevotella spp. DBF NDFU DBF diabetic foot ulcer infection isolates; NDFU non-diabetic foot ulcer isolates. a The data of the NDFU group were taken from the reference 16. b Excluded Streptococcus mitis and S. sanguis. c Excluded Morganella spp., Proteus spp., Providencia spp., Serratia spp., and Yokenella spp.
9 In Vitro Susceptibility Pexiganan 53 to pexiganan, such as Enterococcus faecalis, Proteus mirabilis, and Serratia marcescens. The determination of a susceptibility breakpoint for this topical antimicrobial agent is therefore difficult. To develop useful susceptibility breakpoints for pexiganan, close correlation with efficacy and microbial eradication in clinical infections will need to be performed. Pexiganan was found to be active against bacterial isolates from infected diabetic foot ulcers irrespective of their resistance or susceptibility to other classes of antibiotics. Pexiganan does not exhibit crossresistance with commonly used antibiotics, such as -lactams, quinolones, macrolides, and lincosamides. The lack of cross-resistance between pexiganan and other available antibiotics is likely a reflection of the membrane targeted mechanism of action of this antimicrobial peptide (Hancock, 1997; Jacob and Zasloff, 1994). These features, in combination with its rapidly bactericidal mechanism of action (Ge et al., 1999; Jacob and Zasloff, 1994), warrant further consideration of pexiganan as local therapy for infected diabetic foot ulcers. REFERENCES Boman HG (1995) Peptide antibiotics and their role in innate immunity. Annu Rev Immunol 13: Fuchs PC, Barry AL, Brown SD (1998) In vitro antimicrobial activity of MSI-78, a magainin analog. Antimicrob Agents Chemother 42: Ge Y, MacDonald DL, Holroyd KJ, Thornsberry C, Wexler H, Zasloff M (1999) In vitro antibacterial properties of pexiganan, an analog of Magainin. Antimicrob Agents Chemother 43: Grayson ML, Gibbons GW, Habershaw GM, Freeman DV, Pomposelli FB, Rosenblum BI, Levin E, Karchmer AW (1994) Use of ampicillin/sulbactam versus imipenem/ cilastin in the treatment of life threatening foot infections in diabetic patients. Clin Infect Dis 18: Hancock REW (1997) Peptide antibiotics. Lancet 349: Holzer SE, Camerota A, Martens L, Cuerdon T, Crystal- Peters J, Zagari M (1998) Costs and duration of care for lower extremity ulcers in patients with diabetes. Clin Therpeutics 20: Jacob L, Zasloff MA (1994) Potential therapeutic application of magainins and other antimicrobial agents for animal origin. Ciba Found Symp 186: Levin M (1997) Diabetic foot wounds: pathogenesis and management. Adv Wound Care 10: Lipsky BA, Pecoraro RE, Larson SA, Hanley ME, Ahroni JH (1990) Outpatient management of uncomplicated lower extremity infections in diabetic patients. Arch Intern Med 150: Lipsky BA, Baker PD, Landon GC, Fernau R (1997) Microbial eradication and clinical resolution of infected diabetic foot ulcers treated with topical MSI-78 vs. oral ofloxacin. Abstract from the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy:74. Lipsky BA (1999) Antibiotic therapy of diabetic foot infections. Adv Wound Care, in press. National Committee for Clinical Laboratory Standards (1987) Proposed guideline (M26-P) Approved standard (M11-A): Methods for determining bactericidal activity of antimicrobial agents. Villanova, PA: NCCLS. National Committee for Clinical Laboratory Standards (1993) Approved standard (M11 A3): Methods for antimicrobial susceptibility testing of anaerobic bacteria, 3rd ed. Villanova, PA: NCCLS. National Committee for Clinical Laboratory Standards (1997) Approved standard (M7-A4): Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Villanova, PA: NCCLS. Nicolas P, Mor A (1995) Peptides as weapons against microorganisms in the chemical defense system of vertebrates. Annu Rev Microbiol 49: O Brien JA, Shomphe LA, Kavanagh PL, Raggio G, Caro JJ (1998) Direct medical costs of complications resulting from type 2 diabetes in the United States. Diabetes Care 7:1122. Reiber GE, Lipsky BA, Gibbons GW (1998) The burden of diabetic foot ulcers. Am J Surg 176 (2A Suppl.):5S 10S. West NJ (1995) Systemic antimicrobial treatment of foot infections in diabetic patients. Am J Health Syst Pharm 52: Zasloff MA (1988) Magainins, a class of antimicrobial peptides from Xenopus skin: Isolation, characterization of two active forms, and partial cdna sequence of a precursor. Proc Natl Acad Sci USA 84:
In Vitro Antimicrobial Activity of CP-99,219, a Novel Azabicyclo-Naphthyridone
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 39-353 0066-0/93/0039-05$0.00/0 Copyright 993, American Society for Microbiology Vol. 37, No. In Vitro Antimicrobial Activity of, a Novel Azabicyclo-Naphthyridone
More information2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
More informationIn Vitro Antibacterial Properties of Pexiganan, an Analog of Magainin
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 1999, p. 782 788 Vol. 43, No. 4 0066-4804/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. In Vitro Antibacterial Properties
More information4 th and 5 th generation cephalosporins. Naderi HR Associate professor of Infectious Diseases
4 th and 5 th generation cephalosporins Naderi HR Associate professor of Infectious Diseases Classification Forth generation: Cefclidine, cefepime (Maxipime),cefluprenam, cefoselis,cefozopran, cefpirome
More informationAberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015
Aberdeen Hospital Antibiotic Susceptibility Patterns For Commonly Isolated s For 2015 Services Laboratory Microbiology Department Aberdeen Hospital Nova Scotia Health Authority 835 East River Road New
More informationINFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER
INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER University of Minnesota Health University of Minnesota Medical Center University of Minnesota Masonic Children s Hospital May 2017 Printed herein are
More information2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More information2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More information2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services
2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens
More informationBACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016)
BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) VA Palo Alto Health Care System April 14, 2017 Trisha Nakasone, PharmD, Pharmacy Service Russell Ryono, PharmD, Public Health Surveillance
More information2015 Antibiotic Susceptibility Report
Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens
More information2010 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Children s Hospital
2010 ANTIBIOGRAM University of Alberta Hospital and the Stollery Children s Hospital Medical Microbiology Department of Laboratory Medicine and Pathology Table of Contents Page Introduction..... 2 Antibiogram
More informationAntibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More informationMercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016
Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate
More informationTable 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities.
Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities. Gram-positive cocci: Staphylococcus aureus: *Resistance to penicillin is almost universal. Resistance
More informationC&W Three-Year Cumulative Antibiogram January 2013 December 2015
C&W Three-Year Cumulative Antibiogram January 213 December 215 Division of Microbiology, Virology & Infection Control Department of Pathology & Laboratory Medicine Contents Comments and Limitations...
More information2009 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Childrens Hospital
2009 ANTIBIOGRAM University of Alberta Hospital and the Stollery Childrens Hospital Division of Medical Microbiology Department of Laboratory Medicine and Pathology 2 Table of Contents Page Introduction.....
More informationagainst Clinical Isolates of Gram-Positive Bacteria
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 366-370 Vol. 37, No. 0066-0/93/00366-05$0.00/0 Copyright 993, American Society for Microbiology In Vitro Activity of CP-99,9, a New Fluoroquinolone,
More information2016 Antibiotic Susceptibility Report
Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates
More informationBactiReg3 Event Notes Module Page(s) 4-9 (TUL) Page 1 of 21
www.wslhpt.org 2601 Agriculture Drive Madison, WI 53718 (800) 462-5261 (608) 265-1111 2015-BactiR Reg3 Shipment Date: September 14, 2015 Questions or comments should be directed to Amanda Weiss at 800-462-5261
More informationTel: Fax:
CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.
More informationEvaluation of the BIOGRAM Antimicrobial Susceptibility Test System
JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 1985, p. 793-798 0095-1137/85/110793-06$02.00/0 Copyright 1985, American Society for Microbiology Vol. 22, No. 5 Evaluation of the BIOGRAM Antimicrobial Susceptibility
More informationEpidemiology and Microbiology of Surgical Wound Infections
JOURNAL OF CLINICAL MICROBIOLOGY, Feb. 2000, p. 918 922 Vol. 38, No. 2 0095-1137/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. Epidemiology and Microbiology of Surgical
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIX NUMBER 3 November 2014 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Marti Roe SM MLS (ASCP), Sarah Parker MD, Jason Child PharmD, and Samuel R.
More informationmicrobiology testing services
microbiology testing services You already know Spectra Laboratories for a wide array of dialysis-related testing services. Now get to know us for your microbiology needs. As the leading provider of renal-specific
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More informationScottish Medicines Consortium
Scottish Medicines Consortium daptomycin 350mg powder for concentrate for solution for infusion (Cubicin ) Chiron Corporation Limited No. (248/06) 10 March 2006 The Scottish Medicines Consortium (SMC)
More informationEvaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals
J Vet Diagn Invest :164 168 (1998) Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals Susannah K. Hubert, Phouc Dinh Nguyen, Robert D. Walker Abstract.
More informationRCH antibiotic susceptibility data
RCH antibiotic susceptibility data The following represent RCH antibiotic susceptibility data from 2008. This data is used to inform antibiotic guidelines used at RCH. The data includes all microbiological
More informationQUICK REFERENCE. Pseudomonas aeruginosa. (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.)
Pseudomonas aeruginosa (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.) Description: Greenish gray colonies with some beta-hemolysis around each colony on blood agar (BAP),
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/26062
More informationReassessment of the "Class" Concept of Disk Susceptibility Testing
Reassessment of the "Class" Concept of Disk Susceptibility Testing Disks versus Minimal Inhibitory Concentrations with Eleven Cephalosporins ARTHUR L. BARRY, PH.D., CLYDE THORNSBERRY, PH.D., RONALD N.
More informationHOSPITAL-ACQUIRED INFECTIONS AND QASM PATIENTS
Royal Australasian College of Surgeons Queensland Audit of Surgical Mortality (QASM) HOSPITAL-ACQUIRED INFECTIONS AND QASM PATIENTS (JULY 2011 TO JUNE 2016) Contact Queensland Audit of Surgical Mortality
More informationThe β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018
The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How
More informationHelp with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST
Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to
More informationThe Basics: Using CLSI Antimicrobial Susceptibility Testing Standards
The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information
More informationLeveraging the Lab and Microbiology Department to Optimize Stewardship
Leveraging the Lab and Microbiology Department to Optimize Stewardship Presented by: Andrew Martinez MLS(ASCP), MT(AMT), MBA Alaska Native Medical Center Microbiology Supervisor Maniilaq Health Center
More informationTHE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS
THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology stefanie.desmet@uzleuven.be
More informationجداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی
جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه
More informationAntimicrobial susceptibility
Antimicrobial susceptibility PATTERNS Microbiology Department Canterbury ealth Laboratories and Clinical Pharmacology Department Canterbury District ealth Board March 2011 Contents Preface... Page 1 ANTIMICROBIAL
More informationUSA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION
VIRBAC CORPORATION USA Product Label http://www.vetdepot.com P.O. BOX 162059, FORT WORTH, TX, 76161 Telephone: 817-831-5030 Order Desk: 800-338-3659 Fax: 817-831-8327 Website: www.virbacvet.com CLINTABS
More informationAntimicrobial Susceptibility Testing: Advanced Course
Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to
More informationStudy Type of PCR Primers Identified microorganisms
Study Type of PCR Primers Identified microorganisms Portillo et al, Marín et al, Jacovides et al, Real-time multiplex PCR (SeptiFasta, Roche Diagnostics) 16S rr gene was amplified using conventional PCR.
More informationDoripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities
REVIEW Doripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities Fiona Walsh Department of Clinical Microbiology, Trinity College Dublin, Dublin, Ireland
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007
More informationAntibiotic Stewardship Program (ASP) CHRISTUS SETX
Antibiotic Stewardship Program (ASP) CHRISTUS SETX Program Goals I. Judicious use of antibiotics Decrease use of broad spectrum antibiotics and deescalate use based on clinical symptoms Therapeutic duplication:
More informationAntimicrobial Susceptibility Testing: The Basics
Antimicrobial Susceptibility Testing: The Basics Susan E. Sharp, Ph.D., DABMM, FAAM Director, Airport Way Regional Laboratory Director, Regional Microbiology and Molecular Infectious Diseases Laboratories
More informationEvaluation of the AutoMicrobic System for Susceptibility Testing of Aminoglycosides and Gram-Negative Bacilli
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 1987, p. 546-550 0095-1137/87/030546-05$02.00/0 Copyright C 1987, American Society for Microbiology Vol. 25, No. 3 Evaluation of the AutoMicrobic System for Susceptibility
More informationIn vitro Activity of Gemifloxacin Against Recent Clinical Isolates of Bacteria in Korea
J Korean Med Sci 2002; 17: 737-42 ISSN 1011-8934 Copyright The Korean Academy of Medical Sciences In vitro Activity of Gemifloxacin Against Recent Clinical Isolates of Bacteria in Korea Gemifloxacin is
More informationGuidelines for Laboratory Verification of Performance of the FilmArray BCID System
Guidelines for Laboratory Verification of Performance of the FilmArray BCID System Purpose The Clinical Laboratory Improvement Amendments (CLIA), passed in 1988, establishes quality standards for all laboratory
More informationDrug Class Prior Authorization Criteria Intravenous Antibiotics
Drug Class Prior Authorization Criteria Intravenous Antibiotics Line of Business: Medicaid P&T Approval Date: August 15, 2018 Effective Date: October 1, 2018 This drug class prior authorization criteria
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimal Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) roth dilution: cation-adjusted Mueller-Hinton
More informationPrinciples of Infectious Disease. Dr. Ezra Levy CSUHS PA Program
Principles of Infectious Disease Dr. Ezra Levy CSUHS PA Program I. Microbiology (1) morphology (e.g., cocci, bacilli) (2) growth characteristics (e.g., aerobic vs anaerobic) (3) other qualities (e.g.,
More informationOriginal Article. Hossein Khalili a*, Rasool Soltani b, Sorrosh Negahban c, Alireza Abdollahi d and Keirollah Gholami e.
Iranian Journal of Pharmaceutical Research (22), (2): 559-563 Received: January 2 Accepted: June 2 Copyright 22 by School of Pharmacy Shaheed Beheshti University of Medical Sciences and Health Services
More informationAn evaluation of the susceptibility patterns of Gram-negative organisms isolated in cancer centres with aminoglycoside usage
Journal of Antimicrobial Chemotherapy (1991) 27, Suppl. C, 1-7 An evaluation of the susceptibility patterns of Gram-negative organisms isolated in cancer centres with aminoglycoside usage J. J. Muscato",
More informationLab Exercise: Antibiotics- Evaluation using Kirby Bauer method.
Lab Exercise: Antibiotics- Evaluation using Kirby Bauer method. OBJECTIVES 1. Compare the antimicrobial capabilities of different antibiotics. 2. Compare effectiveness of with different types of bacteria.
More informationReceived 5 February 2004/Returned for modification 16 March 2004/Accepted 7 April 2004
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2004, p. 3112 3118 Vol. 48, No. 8 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.8.3112 3118.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More informationPathogens commonly isolated from selected diseases
Pathogens commonly isolated from selected diseases Equine pneumonia/pleuropneumonia -hemolytic Strep. Clostridium Pasteurella E. coli Klebsiella pneumoniae Bacteroides Equine enteric pathogens Salmonella
More informationCiprofloxacin, Enoxacin, and Ofloxacin against Aerobic and
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 1988, p. 1143-1148 Vol., No. 8 0066-4804/88/081143-06$00/0 Copyright 1988, American Society for Microbiology Comparative Activities of, Amoxicillin-Clavulanic
More informationGive the Right Antibiotics in Trauma Mitchell J Daley, PharmD, BCPS
Give the Right Antibiotics in Trauma Mitchell J Daley, PharmD, BCPS Clinical Pharmacy Specialist, Critical Care Dell Seton Medical Center at the University of Texas and Seton Healthcare Family Clinical
More informationAntibiotic Abyss. Discussion Points. MRSA Treatment Guidelines
Antibiotic Abyss Fredrick M. Abrahamian, D.O., FACEP, FIDSA Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar, California
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXXII NUMBER 6 September 2017 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Stacey Hamilton MT SM (ASCP), Samuel Dominguez MD PhD, Sarah Parker MD, and
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationon February 12, 2018 by guest
AAC Accepted Manuscript Posted Online 12 February 2018 Antimicrob. Agents Chemother. doi:10.1128/aac.00047-18 Copyright 2018 Stapert et al. This is an open-access article distributed under the terms of
More informationMichael Hombach*, Guido V. Bloemberg and Erik C. Böttger
J Antimicrob Chemother 2012; 67: 622 632 doi:10.1093/jac/dkr524 Advance Access publication 13 December 2011 Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011
More information2 0 hr. 2 hr. 4 hr. 8 hr. 10 hr. 12 hr.14 hr. 16 hr. 18 hr. 20 hr. 22 hr. 24 hr. (time)
Key words I μ μ μ μ μ μ μ μ μ μ μ μ μ μ II Fig. 1. Microdilution plate. The dilution step of the antimicrobial agent is prepared in the -well microplate. Serial twofold dilution were prepared according
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationVitek QC Sets. Vitek 2 Identification QC Sets
Vitek 2 Identification QC Sets MicroBioLogics is selling two types of Vitek 2 microorganism identification sets. They are listed below in two columns. The first column lists the 2008 quality control microorganisms
More informationEffect of dalbavancin on the normal intestinal microflora
Journal of Antimicrobial Chemotherapy (00), 1 doi:10.109/jac/dkl1 Advance Access publication 1 July 00 Effect of dalbavancin on the normal intestinal microflora Carl Erik Nord*, Gundars Rasmanis and Elisabeth
More informationCleaning and Disinfection Protocol Vegetative Bacteria
Cleaning and Disinfection Protocol Vegetative Bacteria This document has been developed in accordance with current applicable infection control and biosecurity guidelines. It is intended for use as a guideline
More informationMICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More informationBacterial Pathogens in Urinary Tract Infection and Antibiotic Susceptibility Pattern from a Teaching Hospital, Bengaluru, India
ISSN: 2319-7706 Volume 4 Number 11 (2015) pp. 731-736 http://www.ijcmas.com Original Research Article Bacterial Pathogens in Urinary Tract Infection and Antibiotic Susceptibility Pattern from a Teaching
More informationRecommendations Regarding Use of Rapid Blood Pathogen Identification Panel Data
Recommendations Regarding Use of Rapid Blood Pathogen Identification Panel Data Trevor Van Schooneveld MD, Scott Bergman, PharmD, BCPS, Paul Fey, PhD, Mark Rupp, MD The Clinical Microbiology laboratory
More informationCipro for gram positive cocci in urine
Buscar... Cipro for gram positive cocci in urine 20-6-2017 Pneumonia can be generally defined as an infection of the lung parenchyma, in which consolidation of the affected part and a filling of the alveolar
More informationwith Stability to Dehydropeptidase I
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 99, p. 5- Vol. 33, No. 0066-0/9/005-0$0.00/0 Copyright C 99, American Society for Microbiology In Vitro Antibacterial Activity of, a Carbapenem Antibiotic with
More informationIn Vitro Activity of DR-3355, an Optically Active Ofloxacin
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 1988, p. 1336-1340 0066-4804/88/091336-05$02.00/0 Copyright C 1988, American Society for Microbiology Vol. 32, No. 9 In Vitro Activity of, an Optically Active
More informationCleaning and Disinfection Protocol for Gram-Negative and Gram-Positive Bacteria, including Antibiotic Resistant Bacteria
Cleaning and Disinfection Protocol for Gram-Negative and Gram-Positive Bacteria, including Antibiotic Resistant Bacteria This document has been developed in accordance with current applicable infection
More informationFundamental Concepts in the Use of Antibiotics. Case. Case. TM is a 24 year old male admitted to ICU after TBI and leg fracture from MVA ICU day 3
Fundamental Concepts in the Use of Antibiotics Todd Miano, PharmD, MSCE Critical Care Pharmacist Pharmacoepidemiology Fellow Perelman School of Medicine at the University of Pennsylvania Case TM is a 24
More informationESCMID Online Lecture Library. by author
Expert rules in susceptibility testing EUCAST-ESGARS-EPASG Educational Workshop Linz, 16 19 September, 2014 Dr. Rafael Cantón Hospital Universitario Ramón y Cajal SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Bennett-Guerrero E, Pappas TN, Koltun WA, et al. Gentamicin
More informationAntimicrobial susceptibility testing challenges. Linda Joyce St Vincent s Hospital Melbourne
Antimicrobial susceptibility testing challenges Linda Joyce St Vincent s Hospital Melbourne Bacteria/antimicrobials without breakpoints (B.A.W.B.S.) Enterobacteriacae Pseudomonas aeruginosa, Acinetobacter
More informationAntibiotics. Antimicrobial Drugs. Alexander Fleming 10/18/2017
Antibiotics Antimicrobial Drugs Chapter 20 BIO 220 Antibiotics are compounds produced by fungi or bacteria that inhibit or kill competing microbial species Antimicrobial drugs must display selective toxicity,
More informationSusceptibility Testing and Resistance Phenotypes Detection in Bacterial Pathogens Using the VITEK 2 System
Polish Journal of Microbiology 2005, Vol. 54, No 4, 311 316 Susceptibility Testing and Resistance Phenotypes Detection in Bacterial Pathogens Using the VITEK 2 System EL BIETA STEFANIUK*, AGNIESZKA MRÓWKA
More informationPathogens and Antibiotic Sensitivities in Post- Phacoemulsification Endophthalmitis, Kaiser Permanente, California,
Pathogens and Antibiotic Sensitivities in Post- Phacoemulsification Endophthalmitis, Kaiser Permanente, California, 2007-2012 Geraldine R. Slean, MD, MS 1 ; Neal H. Shorstein, MD 2 ; Liyan Liu, MD, MS
More informationDetection of ESBL Producing Gram Negative Uropathogens and their Antibiotic Resistance Pattern from a Tertiary Care Centre, Bengaluru, India
ISSN: 2319-7706 Volume 4 Number 12 (2015) pp. 578-583 http://www.ijcmas.com Original Research Article Detection of ESBL Producing Gram Negative Uropathogens and their Antibiotic Resistance Pattern from
More informationIn Vitro Activities of the Novel Cephalosporin LB against Multidrug-Resistant Staphylococci and Streptococci
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 2004, p. 53 62 Vol. 48, No. 1 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.1.53 62.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More informationAntimicrobial Susceptibility Patterns
Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department
More informationAntimicrobial Resistance Surveillance from sentinel public hospitals, South Africa, 2013
Antimicrobial Resistance Surveillance from sentinel public s, South Africa, 213 Authors: Olga Perovic 1,2, Melony Fortuin-de Smidt 1, and Verushka Chetty 1 1 National Institute for Communicable Diseases
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimum Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) Broth dilution: cation-adjusted Mueller-Hinton
More informationAntimicrobial Susceptibility Summary 2011
Antimicrobial Susceptibility Summary 2011 Clinical Microbiology Department of Pathology & Laboratory Medicine 45 Antimicrobial Susceptibility Summary Clinical Microbiology Department of Pathology and Laboratory
More informationM45: INFREQUENTLY ISOLATED OR FASTIDIOUS BACTERIA
M45: INFREQUENTLY ISOLATED OR FASTIDIOUS BACTERIA Romney Humphries, PhD D(ABMM) UCLA Clinical Microbiology Under Revision! ORGANISMS INCLUDED IN M45 VS. M100 M100 Enterobacteriaceae Pseudomonas aeruginosa
More information2015 Antimicrobial Susceptibility Report
Gram negative Sepsis Outcome Programme (GNSOP) 2015 Antimicrobial Susceptibility Report Prepared by A/Professor Thomas Gottlieb Concord Hospital Sydney Jan Bell The University of Adelaide Adelaide On behalf
More informationIV Antibiotics for Lyme Disease (Ceftriaxone, Cefotaxime sodium, Doxycycline, Penicillin G potassium)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.15 Subject: IV Antibiotics Lyme Disease Page: 1 of 9 Last Review Date: November 30, 2018 IV Antibiotics
More informationIn vitro activity of telavancin against recent Gram-positive clinical isolates: results of the Prospective European Surveillance Initiative
Journal of Antimicrobial Chemotherapy (2008) 62, 116 121 doi:10.1093/jac/dkn124 Advance Access publication 19 April 2008 In vitro activity of telavancin against recent Gram-positive clinical isolates:
More informationSecondary peritonitis
Secondary peritonitis Caused by spillage of gastrointestinal microorganisms into the peritoneal cavity secondary to loss of the integrity of the mucosal barriers Etiology: perforation of peptic ulcer traumatic
More informationChemotherapy of bacterial infections. Part II. Mechanisms of Resistance. evolution of antimicrobial resistance
Chemotherapy of bacterial infections. Part II. Mechanisms of Resistance evolution of antimicrobial resistance Mechanism of bacterial genetic variability Point mutations may occur in a nucleotide base pair,
More information